Amgen’s KRAS G12C Inhibitor Shows Deep, Durable Efficacy In Lung Cancer
Executive Summary
Results from the Phase II CodeBreak 100 study of sotorasib presented at the World Conference on Lung Cancer were included in Amgen’s applications for approvals in the US, EU and other countries.
You may also be interested in...
Amgen’s Lumakras Efficacy Confirmed In Phase III, But Not As Strong As Phase II
Lumakras data at ESMO in KRAS G12C-mutated lung cancer bested docetaxel on PFS, and largely on safety. OS was better for chemotherapy, but the trial was not powered for statistical significance on OS.
Amgen After ASCO: Questions Remain On Lumakras, Bemarituzumab
Remaining questions after ASCO include whether Lumakras (sotorasib) might work in first-line NSCLC with certain co-mutations and if ocular toxicities will hamper bemarituzumab in gastric cancer.
Amgen’s Sotorasib Updates Raise New Questions For KRAS Program
The company provided updates on the timing of some data from its extensive clinical program for its KRAS G12C inhibitor Lumakras, but not for certain high-profile combinations.